Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology

Preventing Another Stroke: Medications and Health Targets

At a Glance

To prevent another ischemic stroke, treatment must match its cause: antiplatelet medicine for many artery-related strokes, an anticoagulant for atrial fibrillation, and often targets below 130/80 for blood pressure and 70 mg/dL for LDL, plus lifestyle changes and selected carotid procedures.

The goal of your medical team transitions quickly from saving brain tissue to helping you reduce the risk of another stroke. This phase is called secondary prevention. Because having one stroke increases the risk of another, doctors use medications and health targets to protect your brain [1][2].

The specific medications you receive depend entirely on the “why” of your first stroke—the cause identified during your hospital stay. Never start, extend, stop, or combine these drugs without the prescribing team’s instructions.

Protecting Your Arteries: Antiplatelets and DAPT

If your stroke was caused by a clogged artery (atherosclerosis) or a small-vessel blockage, you will likely be prescribed antiplatelet medications. These drugs prevent platelets—the tiny cells that help blood clot—from sticking together [1].

  • Single Therapy: Most patients eventually take one daily pill, such as aspirin or clopidogrel [1].
  • Dual Antiplatelet Therapy (DAPT): Short-course aspirin plus clopidogrel is used mainly for selected early, non-cardioembolic minor ischemic strokes or high-risk TIAs; it is not appropriate for every stroke.
  • The 21-Day Rule: For many of those selected patients, DAPT is most effective during the first 21 days after the event [3][4]. After this window, the risk of serious bleeding usually outweighs the benefit of the second drug, and you will likely be moved back to just one pill [4][5]. Duration can differ for conditions such as symptomatic intracranial stenosis.

Managing Heart Risks: Anticoagulants

If your stroke was caused by atrial fibrillation (an irregular heart rhythm), antiplatelets like aspirin are usually not strong enough. Instead, you will need an anticoagulant, often called a “blood thinner” [6]. Anticoagulants do not dissolve an existing clot; they prevent new ones from forming. Starting anticoagulation after an infarct is timed to infarct size and hemorrhagic risk, not simply to AF detection. If you experience a head injury, fall, or severe bleeding (like dark stools), seek emergency care immediately.

  • DOACs: Modern guidelines prefer Direct Oral Anticoagulants (such as apixaban or rivaroxaban) over the older drug warfarin for appropriate non-valvular atrial fibrillation [6][7]. DOACs are generally safer, causing significantly fewer brain bleeds while being equally effective at preventing clots [7][8].
  • Warfarin: This medication is still required for patients with mechanical heart valves, moderate-to-severe rheumatic mitral stenosis, and certain other conditions [9][10].

Reaching Your ‘Protection Targets’

Taking your pills is only half the effort; reaching specific numbers is also important. These are common targets for many patients, not universal requirements, and they differ from the acute management in the hospital.

  • Blood Pressure (<130/80 mmHg): High blood pressure is the most significant “silent” risk factor for a second stroke [2]. Current guidelines often recommend keeping your pressure below 130/80 mmHg using a combination of medication and diet [2][11].
  • Cholesterol (LDL <70 mg/dL): Even if your cholesterol was “normal” before, you will likely be started on a high-dose statin [12]. The goal for stroke survivors is an LDL (bad cholesterol) level below 70 mg/dL [13][2]. If statins alone don’t reach this target, your doctor may add other medications like ezetimibe or a specialized injection called a PCSK9 inhibitor [14][15].
  • Lifestyle: Secondary prevention also involves smoking cessation, diet optimization, physical activity, sleep apnea screening, and diabetes management (often targeting an A1C < 7%).

Surgical Interventions

If imaging showed a severe blockage in your carotid arteries (the large vessels in your neck), medications may be paired with a procedure to open the “pipe.” Benefit depends on symptomatic, ipsilateral (same-side) carotid stenosis, degree of narrowing, surgical risk, and timing. Complete occlusion is not treated the same way.

  • Carotid Endarterectomy: A surgeon physically removes the plaque from the artery, which is generally favored for many appropriate patients [16].
  • Carotid Stenting: A specialist uses a wire cage (stent) to prop the artery open, reserved for selected situations [17].

These procedures are generally most effective when performed shortly after the stroke or TIA to prevent a follow-up event [16]. Secondary prevention is a lifelong commitment, but with the right combination of medications and monitoring, the risk of a second stroke can be dramatically reduced.

Common questions in this guide

What medicines help prevent a second ischemic stroke?
The choice depends on what caused the stroke. Aspirin or clopidogrel may be used when an artery blockage or small-vessel blockage is responsible, while atrial fibrillation generally calls for an anticoagulant. Never start, stop, extend, or combine these medicines without the prescribing team.
How long should I take aspirin and clopidogrel together after a stroke?
Aspirin plus clopidogrel, known as dual antiplatelet therapy, is only for selected people with an early minor ischemic stroke not caused by a heart clot or a high-risk transient ischemic attack. For many selected patients it lasts about 21 days before returning to one antiplatelet medicine. The duration can differ when there is symptomatic narrowing of an artery inside the brain.
What blood pressure and LDL goals are common after an ischemic stroke?
Common targets for secondary prevention are blood pressure below 130/80 mmHg and LDL cholesterol below 70 mg/dL. These are not universal requirements, so your clinician may adjust them. A high-dose statin is often used, with ezetimibe or a PCSK9 inhibitor added if needed.
Do I need an anticoagulant if I have atrial fibrillation after a stroke?
Atrial fibrillation can allow clots to form in the heart and travel to the brain, so an anticoagulant is usually used instead of aspirin alone. Direct oral anticoagulants such as apixaban or rivaroxaban are generally preferred for appropriate people with non-valvular atrial fibrillation; warfarin is still needed for some mechanical heart valves and certain rheumatic valve disease. The start date after a stroke depends on infarct size and bleeding risk.
When might carotid surgery or stenting be considered?
Carotid endarterectomy or stenting may be considered when imaging shows severe narrowing in the carotid artery on the same side as a recent stroke or transient ischemic attack. The decision depends on the degree of narrowing, timing, surgical risk, and other clinical factors. A completely blocked carotid artery is managed differently.
What bleeding symptoms need emergency attention while taking a blood thinner?
Get emergency care after a head injury or fall while taking a blood thinner, or for severe bleeding such as dark, tarry stools. Do not change or stop your antiplatelet or anticoagulant treatment on your own; seek urgent medical guidance.
Which lifestyle changes can help prevent another stroke?
Stopping smoking, improving diet, staying physically active, being evaluated for sleep apnea, and managing diabetes can all be part of secondary prevention. Taking prescribed medicines and checking blood pressure at home can also help your team track your health targets. Your healthcare team can tailor these steps to your abilities and other conditions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I on one 'antiplatelet' or two (DAPT), and exactly how many days should I stay on both?
  2. 2.Based on my heart rhythm and imaging, do I need a 'blood thinner' (anticoagulant) instead of aspirin?
  3. 3.My target LDL cholesterol is 70 mg/dL—if my next blood test is higher than that, what is the next step after my current statin?
  4. 4.Is my blood pressure goal still 130/80 mmHg, and how often should I check it at home?
  5. 5.If I have narrowing in my neck arteries (carotid stenosis), am I a candidate for surgery or a stent?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.

    Moustafa B, Testai FD

    Current neurology and neuroscience reports 2022; (22(11)):789-802 doi:10.1007/s11910-022-01237-z.

    PMID: 36227497
  2. 2

    European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack.

    Dawson J, Béjot Y, Christensen LM, et al.

    European stroke journal 2022; (7(3)):I-II doi:10.1177/23969873221100032.

    PMID: 36082250
  3. 3

    European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA.

    Dawson J, Merwick Á, Webb A, et al.

    European stroke journal 2021; (6(2)):CLXXXVII-CXCI doi:10.1177/23969873211000877.

    PMID: 34414300
  4. 4

    Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack.

    Brown DL, Levine DA, Albright K, et al.

    Stroke 2021; (52(7)):e468-e479 doi:10.1161/STR.0000000000000377.

    PMID: 34024115
  5. 5

    Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.

    Davis KA, Miyares MA, Dietrich E

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2015; (72(19)):1623-9 doi:10.2146/ajhp140804.

    PMID: 26386103
  6. 6

    Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.

    Klijn CJ, Paciaroni M, Berge E, et al.

    European stroke journal 2019; (4(3)):198-223 doi:10.1177/2396987319841187.

    PMID: 31984228
  7. 7

    Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.

    Carnicelli AP, Hong H, Connolly SJ, et al.

    Circulation 2022; (145(4)):242-255 doi:10.1161/CIRCULATIONAHA.121.056355.

    PMID: 34985309
  8. 8

    Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation.

    Diener HC, Hankey GJ, Easton JD, et al.

    European heart journal supplements : journal of the European Society of Cardiology 2020; (22(Suppl I)):I13-I21 doi:10.1093/eurheartj/suaa104.

    PMID: 33093818
  9. 9

    Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.

    Fanaroff AC, Vora AN, Lopes RD

    European heart journal supplements : journal of the European Society of Cardiology 2022; (24(Suppl A)):A19-A31 doi:10.1093/eurheartj/suab151.

    PMID: 35185406
  10. 10

    Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.

    Fanaroff AC, Ohman EM

    Annual review of medicine 2019; (70()):61-75 doi:10.1146/annurev-med-042617-092334.

    PMID: 30477393
  11. 11

    Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.

    Boncoraglio GB, Del Giovane C, Tramacere I

    Stroke 2021; (52(6)):1974-1982 doi:10.1161/STROKEAHA.120.031945.

    PMID: 33902303
  12. 12

    Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.

    Tramacere I, Boncoraglio GB, Banzi R, et al.

    BMC medicine 2019; (17(1)):67 doi:10.1186/s12916-019-1298-5.

    PMID: 30914063
  13. 13

    A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.

    Amarenco P, Kim JS, Labreuche J, et al.

    The New England journal of medicine 2020; (382(1)):9 doi:10.1056/NEJMoa1910355.

    PMID: 31738483
  14. 14

    The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke.

    Tsankof A, Tziomalos K

    Diseases (Basel, Switzerland) 2021; (10(1)) doi:10.3390/diseases10010003.

    PMID: 35076490
  15. 15

    Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.

    Giugliano RP, Pedersen TR, Saver JL, et al.

    Stroke 2020; (51(5)):1546-1554 doi:10.1161/STROKEAHA.119.027759.

    PMID: 32312223
  16. 16

    Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.

    Bhatia K, Ladd LM, Carr KH, et al.

    Current neurology and neuroscience reports 2023; (23(5)):235-262 doi:10.1007/s11910-023-01266-2.

    PMID: 37037980
  17. 17

    When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy.

    Yuan K, Kim AS

    Current treatment options in cardiovascular medicine 2016; (18(4)):26 doi:10.1007/s11936-016-0449-7.

    PMID: 26909820

This page is for informational purposes only and does not constitute medical advice. Your stroke team should set your medication plan and blood pressure and cholesterol targets; never change antiplatelet or anticoagulant treatment without medical guidance.

Get notified when new evidence is published on ischemic stroke.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.